{"protocolSection": {"identificationModule": {"nctId": "NCT02268500", "orgStudyIdInfo": {"id": "2014-0656"}, "organization": {"fullName": "University of Wisconsin, Madison", "class": "OTHER"}, "briefTitle": "VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)", "officialTitle": "VAccination to Improve Clinical outComes in Heart Failure Trial (VACC-HeFT): a Feasibility Study", "acronym": "VACC-HeFT"}, "statusModule": {"statusVerifiedDate": "2021-06", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-09"}, "primaryCompletionDateStruct": {"date": "2016-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2016-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-10-08", "studyFirstSubmitQcDate": "2014-10-15", "studyFirstPostDateStruct": {"date": "2014-10-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-04-28", "resultsFirstSubmitQcDate": "2021-06-08", "resultsFirstPostDateStruct": {"date": "2021-06-09", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-06-08", "lastUpdatePostDateStruct": {"date": "2021-06-09", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Wisconsin, Madison", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "A multi-center, prospective, randomized, open-label blinded-endpoint trial in patients with heart failure will be conducted; 20 will be assigned to the standard dose vaccine dose and 20 patients to high dose influenza vaccine. Post-vaccine antibody measurements will be assessed, as well as tolerability differences between groups.", "detailedDescription": "This is a randomized, double blind, active-control trial of high dose influenza vaccine compared to standard dose influenza vaccine for one season in adult participants with symptomatic heart failure(HF). The primary outcome measure is humoral (antibody-mediated) immune response, and secondary outcomes include cumulative incidence of influenza-like illness symptoms and all cause hospitalizations. The aim is to gather information on feasibility of this study design and effect size differences to inform a larger outcomes-based clinical trial.\n\nThe 5.8 million Individuals in the US with heart HF are at high risk for influenza infection and associated morbidity, mortality and increased health care costs despite annual influenza vaccination. Higher dose of vaccine is approved for use in older adults. Antibody-mediated immunity contributes to vaccine-induced protection from influenza illness. Investigators at University of Wisconsin(UW) Madison have demonstrated reduced antibody titers to influenza vaccination in patients with HF. Additionally, study team has shown in a pilot study that double dose influenza vaccine resulted in increased titers and was well tolerated.\n\nA multi-center, prospective, randomized, open-label blinded-endpoint trial will be conducted with 20 participants assigned to the standard dose vaccine dose and 20 participants to high dose influenza vaccine. The primary outcome measure is the rate of seroconversion (4-fold rise in antibody titers to A/H3N2, A/H1N1, and B-type vaccine antigens), assessed 4 weeks post vaccination. The study will also examine feasibility differences in symptoms of influenza and all-cause hospitalizations between vaccine dose groups, and these data will be used for planning a subsequent outcomes-based clinical trial."}, "conditionsModule": {"conditions": ["Chronic Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 48, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Standard dose influenza vaccine", "type": "ACTIVE_COMPARATOR", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly", "interventionNames": ["Biological: Influenza vaccine"]}, {"label": "High dose influenza vaccine", "type": "ACTIVE_COMPARATOR", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly", "interventionNames": ["Biological: Influenza vaccine"]}], "interventions": [{"type": "BIOLOGICAL", "name": "Influenza vaccine", "description": "Influenza vaccine", "armGroupLabels": ["High dose influenza vaccine", "Standard dose influenza vaccine"], "otherNames": ["Fluzone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens", "timeFrame": "4 weeks"}, {"measure": "Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H3N2 Vaccine Antigens", "timeFrame": "4 weeks"}, {"measure": "Number of Participants With 4 Fold Rise in Serum Antibody Concentration of B-type Vaccine Antigens", "timeFrame": "4 weeks"}], "secondaryOutcomes": [{"measure": "Number of Participants With Influenza Like Illness", "description": "Influenza Like Illness is not considered adverse event.", "timeFrame": "8 months"}, {"measure": "Number of All-cause Hospitalizations", "description": "All-cause hospitalizations are not considered adverse events.", "timeFrame": "8 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults \\> 18 years old\n2. Able to give informed consent\n3. Systolic or diastolic dysfunction\n4. Previously or currently symptomatic heart failure\n5. Stable on current heart failure drug therapy regimen for \\> 30 days and no change in heart failure drug therapy regimen on day of enrollment\n6. Hospitalization (for any reason) in last 12 months\n7. Received influenza vaccination the prior season\n\nExclusion Criteria:\n\n1. History of allergic reaction or adverse event to influenza vaccine\n2. Documented severe allergy to egg products\n3. Unwilling or unable to give consent\n4. Moderate to severe acute febrile illness at baseline\n5. Immunologic conditions that may affect immune responses per clinical judgment of the investigators\n6. Use of immunosuppressants or immunomodulating therapies within 3 months of the study, including prednisone, cyclosporine, tacrolimus, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, and injectable interferons\n7. Participation in a clinical trial within 30 days\n8. Absence for more than 7 consecutive days during the surveillance period", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Orly Vardeny, PharmD, MS", "affiliation": "University of Wisconsin, Madison", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Wisconsin Hospital and Clinics", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "FG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "24"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "BG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "48"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "56.4", "spread": "12.2"}, {"groupId": "BG001", "value": "62.5", "spread": "13.1"}, {"groupId": "BG002", "value": "59.45", "spread": "12.7"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "10"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "21"}, {"groupId": "BG002", "value": "38"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "47"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "47"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Left Ventricular Ejection Fraction (LVEF) percentage", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of ejection fraction", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.8", "spread": "9.8"}, {"groupId": "BG001", "value": "40.3", "spread": "10.2"}, {"groupId": "BG002", "value": "39.55", "spread": "10"}]}]}]}, {"title": "Body mass index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "33.7", "spread": "10"}, {"groupId": "BG001", "value": "30.9", "spread": "6.8"}, {"groupId": "BG002", "value": "32.3", "spread": "8.4"}]}]}]}, {"title": "number of current tobacco users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Participants with Diabetes mellitus", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "15"}]}]}]}, {"title": "Participants with Atrial fibrillation", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "21"}]}]}]}, {"title": "Participants with Ischemic etiology", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "14"}]}]}]}, {"title": "Aspirin users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "32"}]}]}]}, {"title": "Angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "23"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "46"}]}]}]}, {"title": "Beta blocker users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "23"}, {"groupId": "BG002", "value": "45"}]}]}]}, {"title": "Mineralocorticoid Receptor Antagonists (MRA) users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "17"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "30"}]}]}]}, {"title": "Diuretic users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "19"}, {"groupId": "BG002", "value": "39"}]}]}]}, {"title": "Long acting nitrate users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}]}]}, {"title": "Number of Digoxin users", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "11"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens", "populationDescription": "1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "OG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.89", "statisticalMethod": "Chi-squared"}]}, {"type": "PRIMARY", "title": "Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H3N2 Vaccine Antigens", "populationDescription": "1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "OG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "17"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.43", "statisticalMethod": "Chi-squared"}]}, {"type": "PRIMARY", "title": "Number of Participants With 4 Fold Rise in Serum Antibody Concentration of B-type Vaccine Antigens", "populationDescription": "1 participant from 'standard dose influenza vaccine' arm and 1 participant from 'high dose influenza vaccine' arm were excluded as the sample was inadequate to run the assay.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "4 weeks", "groups": [{"id": "OG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "OG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "23"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.03", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of Participants With Influenza Like Illness", "description": "Influenza Like Illness is not considered adverse event.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "8 months", "groups": [{"id": "OG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "OG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.76", "statisticalMethod": "Chi-squared"}]}, {"type": "SECONDARY", "title": "Number of All-cause Hospitalizations", "description": "All-cause hospitalizations are not considered adverse events.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "hospitalizations", "timeFrame": "8 months", "groups": [{"id": "OG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}, {"id": "OG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "24"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "15"}, {"groupId": "OG001", "value": "6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.01", "statisticalMethod": "Chi-squared"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "1 week", "description": "1 week post randomization, participants were contacted by phone for ascertainment of injection related adverse events.", "eventGroups": [{"id": "EG000", "title": "Standard Dose Influenza Vaccine", "description": "Standard dose (45ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine", "deathsNumAffected": 1, "deathsNumAtRisk": 24, "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 0, "otherNumAtRisk": 24}, {"id": "EG001", "title": "High Dose Influenza Vaccine", "description": "High dose (180ug) influenza vaccine will be administered intramuscularly\n\nInfluenza vaccine: Influenza vaccine", "deathsNumAffected": 0, "deathsNumAtRisk": 24, "seriousNumAffected": 0, "seriousNumAtRisk": 24, "otherNumAffected": 0, "otherNumAtRisk": 24}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Orly Vardeny, Associate Professor of Medicine", "organization": "University of Minnesota", "email": "ovardeny@umn.edu", "phone": "612.467.4586"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M17360", "name": "Vaccines", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}